


## RESPONSE

### 1. Restriction

The Restriction Requirement asserts that restriction between claims 1-13 is proper and requests that Applicants elect for further prosecution one of Groups I-II, wherein Group I consists of claims 1-6 and Group II consists of claims 7-13. Applicants elect Group II claims 7-13, without traverse.

At page 3, the restriction requirement further requires Applicants to elect a single disclosed species for prosecution on the merits to which claims shall be restricted if no generic claim is finally held to be allowable. In underlined text, Applicants are requested to “... elect a particular combination of two ore [sic] more compounds from amongst those recited in claims 1 or 8 [it is believed that the Examiner means claims 1 or 7], including a corresponding analyte from amongst the following: ...”. Because Applicants are compelled to make said election, Applicants elect the combination of fragment ions derived from labeled analytes of formula:



wherein the analyte is a protein or peptide. Applicants believe that claims 7, 8 and 13 read on this elected combination. Applicants further believe that because of the amendment set forth above, claims 14, 15 and 20 also read on this elected combination.

### 2. Amendment

The amendment set forth above cancels claims 1-6 pursuant to the Restriction Requirement. The amendment set forth above also clarifies the claim language of claim 7. Antecedent basis for these changes can be found throughout the specification but in particular at page 20, line 11 to page 27, line 10. Newly added claims 14-20 mirror claims 7-13 except that claim 14 does not require that the fragmentation and analysis be performed in a tandem mass spectrometer. Antecedent basis for this amendment can be found throughout the specification but in particular at page 26, line 21 to page 27, line 10.

It is believed that no new matter has been added by this amendment.

3. Other Co-Pending Applications Owned by Applera Corporation

For the convenience of the Examiner, reference is made to the following copending applications owned by Applera Corporation. The Examiner is invited to review the claims of these applications for consideration of any issue and for purposes of any obviousness type double patenting rejections. Undersigned Applicants' counsel is also available to discuss the state of prosecution or an issue related to the status of the foregoing to assist the Examiner in any way needed.

<b>Title</b>	<b>Serial No.</b>	<b>Filing Date</b>
Methods And Mixtures Pertaining To Analyte Determination	10/765,458	27 Jan 2004
Methods And Mixtures Pertaining To Analyte Determination Using Electrophilic Labeling Reagents	10/765,264	27 Jan 2004
Compositions And Kits Pertaining To Analyte Determination	10/765,267	27 Jan 2004
Method And Apparatus For De-Convoluting A Convolved Spectrum	10/916,629	12 Aug 2004
Analysis Of Mass Spectral Data In The Quiet Zones	10/999,638	24 Nov 2004
Active Esters of N-Substituted Piperazine Acetic Acids, Including Isotopically Enriched Versions Thereof	10/751,354	05 Jan 2004
Isotopically Enriched N-Substituted Piperazine Acetic Acids And Methods For The Preparation Thereof	10/751,387	05 Jan 2004
Isotopically Enriched N-Substituted Piperazines And Methods For The Preparation Thereof	10/751,388	05 Jan 2004
Isobarically Labeled Analytes And Fragment Ions Derived Therefrom	10/852,730	24 May 2004
Determination of Analyte Characteristics Based Upon Affinity Binding Properties	11/069,277	01 Mar 2005
Preparation Of Biologically Derived Fluids For Biomarker Determination By Mass Spectrometry	11/051,807	04 Feb 2005
Isobaric-Coded Mass Tags for Quantitative Protein Analyses with Tandem MS	11/179,060	11 Jul 2005
Mixtures of Isobarically Labeled Analytes and Fragment Ions Derived Therefrom	10/751,353	05 Jan 2004
Kits Pertaining to Analyte Determination	11/623,510	16 Jan 2007
Sets and Compositions Pertaining to Analyte Determination	11/673,809	12 Feb 2007
Analyte Determination Utilizing Mass Tagging Reagents Comprising a Non-Encoded Detectable Label	11/769,890	28 Jun 2007
Methods, Mixtures, Kits and Compositions Pertaining to Analyte Determination	11/625,688	22 Jan 2007

Methods, Mixtures, Kits and Compositions Pertaining to Analyte Determination	11/319,685	28 Dec 2005
Methods, Mixtures, Kits and Compositions Pertaining to Analyte Determination	11/770,212	28 Jun 2007
Mixtures of Isobarically Labeled Analytes and Fragment Ions Derived Therefrom	10/822,639	12 Apr 2004
Isotopically Enriched N-Substituted Piperazines and Methods for the Preparation Thereof	12/001,734	11 Dec 2007
Methods, Compositions and Kits Pertaining to Analyte Determination	11/970,470	07 Jan 2008


It is believed that this response addresses all the issues raised in the present Action and the application is in ready condition for allowance. In consideration of the preceding amendments and remarks, Applicants hereby respectfully request reconsideration of all pending claims and the issuance of a Notice of Allowance by The Office.

If the Examiner believes a telephonic or personal interview would advance the prosecution of the subject application, the Examiner is invited to contact attorney Kurt T. Mulville during business hours at the telephone or facsimile numbers listed below.

Please charge \$460.00 for a two month extension fee to Applied BioSystems, Inc.'s Deposit Account No. **01-2213** for the above fee(s). The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Applied BioSystems, Inc.'s Deposit Account No. **01-2213**.

Respectfully submitted,

ORRICK, HERRINGTON & SUTCLIFFE LLP

By:   
Kurt T. Mulville, Reg. No. 37,194

Dated: January 10, 2008

Orrick, Herrington & Sutcliffe LLP  
4 Park Plaza, Suite 1600  
Irvine, CA 92614  
Tel: 949/567-6700  
Fax: 949/567-6710  
Customer Number 34313